Amarin Corporation plc (AMRN)

Amarin Corporation plc, a biopharmaceutical company, engages in the research, development, and commercialization of drugs for patients suffering from central nervous system (CNS) and cardiovascular diseases. The company’s CNS development pipeline includes AMR101, a semi-synthetic and highly purified derivative of 5,8,11,14,17-eicosapentaenoic acid for the treatment of dyslipidemia and Huntington's disease; EN101, an orally available antisense oligonucleotide for myasthenia gravis; sublingual Apomorphine for Parkinson's disease; Nasal Lorazepam for the treatment of emergency seizures in epilepsy patients; and AMR101 to treat associated memory impairment. In addition, it has two proprietary technology platforms, which include targeted lipid transport technology platform for the targeted transport of molecules through the liver and/or to the brain; and messenger RNA technology based on cholinergic neuromodulation. Amarin Corporation operates in the United Kingdom and internationally. The company has a collaboration agreement with ProSeed Capital Holdings CVA. Amarin Corporation plc formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.

0For the six months ended 30 June 2006, Amarin Corporation PLC's, revenues remained flat at $0. Net loss increased 35% to $13.2M. Revenues reflect the absence of sales due to discontinued operations. Higher loss reflects an increase in research & development expenses, higher selling, general & administrative expenses, the presence of group restructuring expenses and increased non cash share based compensation expense.